Ngo D, Magana A, Tran T, Sklenicka J, Phan K, Eykholt B
Pharmaceuticals (Basel). 2023; 16(2).
PMID: 37259383
PMC: 9966628.
DOI: 10.3390/ph16020236.
Logviniuk D, Jaber Q, Dobrovetsky R, Kozer N, Ksiezopolska E, Gabaldon T
J Am Chem Soc. 2022; 144(13):5965-5975.
PMID: 35347986
PMC: 8991007.
DOI: 10.1021/jacs.2c00269.
Zhou S, Chen X, Ni X, Liu Y, Zhang H, Dong M
Microb Cell Fact. 2021; 20(1):65.
PMID: 33750386
PMC: 7941887.
DOI: 10.1186/s12934-021-01558-7.
Ban Y, Song M, Hwang J, Shin H, Kim H, Hong S
Nat Chem Biol. 2019; 15(3):295-303.
PMID: 30643280
PMC: 6488028.
DOI: 10.1038/s41589-018-0203-4.
Zarate S, De la Cruz Claure M, Benito-Arenas R, Revuelta J, Santana A, Bastida A
Molecules. 2018; 23(2).
PMID: 29385736
PMC: 6017855.
DOI: 10.3390/molecules23020284.
Amikacin: Uses, Resistance, and Prospects for Inhibition.
Ramirez M, Tolmasky M
Molecules. 2017; 22(12).
PMID: 29257114
PMC: 5889950.
DOI: 10.3390/molecules22122267.
Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.
Takahashi Y, Igarashi M
J Antibiot (Tokyo). 2017; .
PMID: 29066797
DOI: 10.1038/ja.2017.117.
Synthesis and antibacterial activity of 1-N-[(S)-ω-amino-2-hydroxyalkyl] derivatives of dibekacin, 5-deoxydibekacin, 3'-deoxykanamycin A and gentamicin B.
Umemura E, Sakamoto Y, Takahashi Y, Miyake T
J Antibiot (Tokyo). 2015; 68(6):421-3.
PMID: 25712399
DOI: 10.1038/ja.2015.6.
Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.
Shi K, Caldwell S, Fong D, Berghuis A
Front Cell Infect Microbiol. 2013; 3:22.
PMID: 23805415
PMC: 3691515.
DOI: 10.3389/fcimb.2013.00022.
Inhibition of aminoglycoside-deactivating enzymes APH(3')-IIIa and AAC(6')-Ii by amphiphilic paromomycin O2''-ether analogues.
Szychowski J, Kondo J, Zahr O, Auclair K, Westhof E, Hanessian S
ChemMedChem. 2011; 6(11):1961-6.
PMID: 21905229
PMC: 5179253.
DOI: 10.1002/cmdc.201100346.
Aminoglycosides: activity and resistance.
Mingeot-Leclercq M, Glupczynski Y, Tulkens P
Antimicrob Agents Chemother. 1999; 43(4):727-37.
PMID: 10103173
PMC: 89199.
DOI: 10.1128/AAC.43.4.727.
Comparative nephrotoxicities of dibekacin, amikacin, and gentamicin in a rat model.
Rankin L, Luft F, Yum M, Isaacs L
Antimicrob Agents Chemother. 1980; 18(6):983-5.
PMID: 7235685
PMC: 353003.
DOI: 10.1128/AAC.18.6.983.
In vitro comparison of dibekacin and gentamicin activities.
Hill C, COUNTS G, Turck M
Antimicrob Agents Chemother. 1981; 19(1):190-2.
PMID: 6787978
PMC: 181381.
DOI: 10.1128/AAC.19.1.190.
Pharmacokinetic studies with dibekacin, a new aminoglycoside, after intravenous and intramuscular administration to human volunteers.
Goto M, Sugiyama M, Ishizaki T
Antimicrob Agents Chemother. 1980; 18(3):372-6.
PMID: 6775594
PMC: 284008.
DOI: 10.1128/AAC.18.3.372.
Neuromuscular blocking activity of dibekacin, a new semisynthetic aminoglycoside antibiotic.
Paradelis A, Tsouras J, Latsoudes P, Demetriou T, Triantaphyllidis C
Experientia. 1980; 36(7):867-8.
PMID: 6772469
DOI: 10.1007/BF01978619.
Sisomicin, netilmicin and dibekacin. A review of their antibacterial activity and therapeutic use.
Noone P
Drugs. 1984; 27(6):548-78.
PMID: 6376062
DOI: 10.2165/00003495-198427060-00003.
Phosphorylation of lividomycin by Escherichia coli carrying an R factor.
Yamaguchi M, Koshi T, Kobayashi F, Mitsuhashi S
Antimicrob Agents Chemother. 1973; 2(3):142-6.
PMID: 4597704
PMC: 444281.
DOI: 10.1128/AAC.2.3.142.
Mechanisms and spectrum of streptomycin resistance in a natural population of Pseudomonas aeruginosa.
Tseng J, Bryan L, van den Elzen H
Antimicrob Agents Chemother. 1973; 2(3):136-41.
PMID: 4208274
PMC: 444280.
DOI: 10.1128/AAC.2.3.136.
Aminoglycoside research 1975-1985: prospects for development of improved agents.
PRICE K
Antimicrob Agents Chemother. 1986; 29(4):543-8.
PMID: 3518623
PMC: 180438.
DOI: 10.1128/AAC.29.4.543.
Chemistry of newer antibiotics directed toward overcoming bacterial resistance.
Mitscher L
Bull N Y Acad Med. 1987; 63(3):269-94.
PMID: 3300828
PMC: 1629233.
